Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods
| Autor: | Camille Tron, Florian Lemaitre, Pauline Bros, Claire Goulvestre, Bénédicte Franck, Nicolas Mouton, Sandrine Bagnos, Romain Coriat, Nihel Khoudour, Dorothée Lebert, Benoit Blanchet |
|---|---|
| Přispěvatelé: | CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), PROteomics and METabolomics Platform [Grenoble] (PROMETHEE), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cibles Thérapeutiques et conception de médicaments (CiTCoM - UMR 8038), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), P Bros, S Bagnos N Mouton and D Lebert are employed by Promise Proteomics. B Blanchet has received honoraria from Promise Proteomics for consulting services. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed., Jonchère, Laurent |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
musculoskeletal diseases
therapeutic drug monitoring [SDV]Life Sciences [q-bio] Clinical Biochemistry Enzyme-Linked Immunosorbent Assay General Medicine MS Analytical Chemistry LC-MS [SDV] Life Sciences [q-bio] Medical Laboratory Technology Tandem Mass Spectrometry adalimumab Humans ELISA General Pharmacology Toxicology and Pharmaceutics skin and connective tissue diseases infliximab Chromatography Liquid |
| Zdroj: | Bioanalysis Bioanalysis, 2022, 14 (11), pp.831-844. ⟨10.4155/bio-2022-0057⟩ |
| ISSN: | 1757-6180 1757-6199 |
| DOI: | 10.4155/bio-2022-0057⟩ |
| Popis: | International audience; Background: This study compared the performance of plasma infliximab and adalimumab quantification using a commercially available kit (mAbXmise kit) and mass spectrometry readout to that of two ELISA methods in patients treated for inflammatory bowel disease. Methods and results: The mAbXmise method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) was linear from 2 to 100 mu g/ml. It was validated according to international guidelines. Regarding cross-validation for infliximab (n = 70), the mean bias with LC-MS/MS assay was approximately threefold higher with the commercial ELISA assay compared with the in-house ELISA (-6.1 vs -1.8 mu g/ml, respectively). The mean bias between the LC-MS/MS assay and in-house ELISA was -1.2 mu g/ml for adalimumab (n = 35). Conclusion: The LC-MS/MS method is a powerful alternative to immunoassays to monitor concentrations of infliximab and adalimumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|